Bayer stock forecast: $7.25bn Roundup settlement delay
Bayer is a German life sciences company active in pharmaceuticals and crop science, currently navigating a proposed $7.25bn Roundup settlement and regulatory developments including a new UK indication for Eylea. Explore third-party BAYN price targets and technical analysis.
Bayer AG (BAYN) is trading around €42.60 in late European dealings at 5:12pm (UTC) on 25 February 2026, within an intraday range of €41.90–€42.75. Past performance is not a reliable indicator of future results.
The session comes amid renewed focus on Bayer’s proposed $7.25bn Roundup settlement after a court filing showed some plaintiffs seeking to delay preliminary approval (Reuters, 25 February 2026). Separate reports outline the group’s efforts to contain glyphosate-related litigation expenses and provide guidance on expected cash flow impacts (AgTechNavigator, 18 February 2026). In the healthcare segment, UK regulators have cleared an additional retinal indication for Eylea (PharmiWeb.com, 25 February 2026). At the same time, Bayer is pursuing legal action in the US over alleged false advertising claims related to its prostate cancer drug Nubeqa and a rival therapy (Investing.com, 24 February 2026).
Bayer stock forecast 2026–2030: Third-party price targets
As of 25 February 2026, third-party Bayer stock predictions range from the mid-€20s to the mid-€40s, alongside corresponding dollar levels for its ADRs. This dispersion reflects differing assessments of litigation cash outflows, leverage and the earnings outlook across pharmaceuticals and crop science. The February 2026 snapshots below summarise selected 12-month price objectives and the assumptions cited by each source.
Jefferies (broker research update)
Jefferies maintains a Hold rating on Bayer with a 12-month BAYN stock forecast of €25 per share. Analyst Chris Counihan reiterates this objective as the bank assesses the proposed $7.25bn Roundup class settlement. The note states that the view incorporates expectations of negative free cash flow in 2026 due to settlement payments, alongside residual risks linked to court approval and a pending US Supreme Court review (MarketScreener, 17 February 2026).
Simply Wall St (analyst-compiled target snapshot)
Simply Wall St reports that Bayer traded around €45.81 compared with a compiled analyst price target of €43.68 per share, implying the stock stood approximately 4.9% above that blended objective at the time of publication. The service aggregates multiple analyst forecasts and notes that the target reflects ongoing reassessment of Roundup settlement terms and their valuation impact (Simply Wall St, 19 February 2026).
Reuters (coverage consensus and recommendation)
Reuters reports that Bayer is covered by 23 analysts with a consensus recommendation classified as ‘Outperform’ on its 2.48-point scale. The compiled 12-month price target range spans both downside and upside scenarios. According to the agency, the wide dispersion of targets reflects differing assumptions about glyphosate litigation, cost-saving measures and the performance of Bayer’s key therapeutic and crop science franchises (Reuters, 19 February 2026).
MarketWatch (ADR price-target distribution)
MarketWatch’s Bayer AG ADR (BAYRY) analyst estimates page shows an average 12-month target of about $13.09 per ADR. The range extends from a high of $17.73 to a low of $6.71, compared with a prevailing price of roughly $12.81 at the time of the snapshot. These figures aggregate several analyst models that weigh potential earnings normalisation against litigation, leverage and restructuring risks (MarketWatch, 21 February 2026).
TipRanks (BAYRY target and implied downside)
TipRanks indicates that the average BAYRY price target among its tracked analysts stood at $12.35 per ADR, which it said implied around 14.2% downside from then-current levels following a roughly 155% share price rally over the prior year. The article states that analysts factor in both the proposed $7.25bn settlement and expectations for future cash generation and debt reduction (TipRanks, 18 February 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
BAYN stock price: Technical overview
The BAYN stock price trades near €42.60 as of 5:12pm UTC on 25 February 2026, holding just above the Classic pivot at 42.723 after testing an intraday band between 41.90 and 42.75. The daily simple moving average (SMA) cluster sits around the 20-, 50-, 100- and 200-day levels at approximately 45, 42, 35 and 31 respectively. This places the price below the shorter-term averages but above the longer-term trend measures. The 14-day relative strength index (RSI) stands near 44, indicating mid-range momentum, while the average directional index (ADX) around 34 suggests an established trend rather than a developing one.
On the topside, traders often monitor the classic R1 pivot near 48.572, with R2 around 52.583 coming into view only if price records a sustained daily close above the first resistance zone. On pullbacks, the classic pivot near 42.723 may act as initial support. Below this, the 100-day SMA near 35 represents a further reference level, while the S1 area around 38.712 may attract attention if selling pressure increases (TradingView, 25 February 2026).
Technical analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Bayer share price history (2024–2026)
BAYN’s stock price moved from around €28 in late February 2024 to €42.60 at the close on 25 February 2026. During 2024, the stock traded mostly in the mid- to high-€20s before falling below €20 by December. From early 2025, the price rebounded from around €19–€20 and broke above €30 by November, ending the year near €37.
In early 2026, the rally extended as the price moved from just above €38 in early January to test levels close to €50 in mid-February, before consolidating back into the low-€40s into the latest session. This period illustrates how quickly sentiment and positioning can shift in response to legal, operational and broader market developments.
Past performance is not a reliable indicator of future results.
Bayer (BAYN): Capital.com analyst view
Over the past two years, Bayer’s share price has transitioned from a prolonged period in the high-teens and low-€20s to a sharper upswing that carried the stock above €40 and briefly close to €50 in early 2026. This re-rating coincided with a reassessment of litigation risks, balance sheet pressures and earnings prospects across its pharmaceutical and crop science divisions.
However, these factors remain fluid. If cash flows underperform expectations, legal costs exceed current projections or sector sentiment deteriorates, valuations could adjust. Conversely, more favourable legal outcomes, improved operating performance or clearer visibility on debt reduction may influence investor confidence. As a result, price action may continue to reflect shifting assumptions rather than a single, fixed narrative.
Capital.com’s client sentiment for Bayer CFDs
As of 25 February 2026, Capital.com client positioning in Bayer shows 95.3% buyers versus 4.7% sellers, a net long bias of approximately 90.6 percentage points. This snapshot reflects open positions on the Capital.com platform at the time of writing and may change as market conditions evolve. Client sentiment data should not be viewed in isolation and does not indicate future price direction.
Summary – Bayer 2026
- As of 5:12pm UTC on 25 February 2026, Bayer traded near €42.60, well above sub-€20 levels seen in late 2024 and below-€30 levels in early 2025.
- Technical indicators place the price above longer-term moving averages but below shorter-term SMAs, with the RSI in mid-range territory and the ADX signalling an established trend.
- Key drivers include developments around the proposed $7.25bn Roundup settlement, expectations for cash flow and leverage, and performance across pharmaceuticals and crop science.
- Recent headlines focus on the Roundup agreement and related legal proceedings, regulatory updates such as Eylea’s additional indication, and ongoing advertising disputes in the US.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Bayer stock?
Bayer’s largest shareholders typically include institutional investors, asset managers and pension funds, alongside retail investors. Holdings can change over time as funds adjust their exposure in response to company performance, index weightings or broader market conditions. Public filings and regulatory disclosures provide the most current breakdown of significant shareholdings. As ownership structures evolve, concentration levels may influence liquidity and voting dynamics, although they do not necessarily determine short-term share price movements.
What is the five-year Bayer share price forecast?
There is no single, agreed five-year BAYN stock forecast. Most publicly available targets focus on 12-month horizons, and even these vary depending on assumptions about litigation outcomes, debt levels, earnings growth and sector trends. Longer-term projections involve additional uncertainty, particularly where legal liabilities and restructuring plans remain under review. Investors often assess a range of scenarios rather than relying on one fixed estimate.
Is Bayer a good stock to buy?
Whether Bayer is considered a ‘good’ stock depends on an individual’s objectives, risk tolerance and time horizon. The company operates across pharmaceuticals and crop science, but it also faces ongoing litigation and balance sheet considerations. Some analysts point to potential earnings stabilisation, while others highlight legal and leverage risks. Share price volatility in recent years reflects these competing factors. This information is general and does not constitute investment advice.
Could Bayer stock go up or down?
Bayer’s share price can move in either direction depending on legal developments, earnings results, regulatory updates and broader equity market conditions. News related to glyphosate litigation, settlement approvals or cash flow guidance may influence market sentiment. At the same time, macroeconomic factors such as interest rates, currency movements and sector allocation decisions can affect valuations. As with any listed equity, price movements may be sharp, and past performance is not a reliable indicator of future results.
Should I invest in Bayer stock?
Deciding whether to invest in Bayer shares requires careful consideration of your financial situation, investment goals and appetite for risk. The company’s outlook reflects operational performance as well as ongoing legal proceedings, which may affect future cash flows and balance sheet strength. Investors typically review analyst research, financial statements and industry conditions before making a decision. If you are unsure, you may wish to seek independent financial advice. This content is provided for informational purposes only.
Can I trade Bayer CFDs on Capital.com?
Yes, you can trade Bayer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.